Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has announced the approval of a proposed listing of its indirect non-wholly owned subsidiary, Shijiazhuang Innovation, on the Hong Kong Stock Exchange (HKEX) main board, expected to be completed by September 30, 2025 [1] Summary by Relevant Sections - Proposed Listing: The board of Shijiazhuang Innovation has approved the proposal for H-share listing on the HKEX [1] - Ownership Impact: Following the completion of the H-share listing, the company's ownership percentage in Shijiazhuang Innovation is expected to decrease by approximately 8.46%, resulting in the company holding about 66.20% of the subsidiary's equity [1] - Share Issuance: The proposed listing includes the issuance of shares and an over-allotment option, which, if fully exercised, will affect the company's equity stake [1]
石药集团(01093)：石药创新建议于联交所主板上市